An experimental and theoretical study of the inhibition of Escherichia coli lac operon gene expression by antigene oligonucleotides.
Previously, we have developed a genetically structured mathematical model to describe the inhibition of Escherichia coli lac operon gene expression by antigene oligos. Our model predicted that antigene oligos targeted to the operator region of the lac operon would have a significant inhibitory effect on beta-galactosidase production. In this investigation, the E. coli lac operon gene expression in the presence of antigene oligos was studied experimentally. A 21-mer oligo, which was designed to form a triplex with the operator, was found to be able to specifically inhibit beta-galactosidase production in a dose-dependent manner. In contrast to the 21-mer triplex-forming oligonucleotide (TFO), several control oligos showed no inhibitory effect. The ineffectiveness of the various control oligos, along with the fact that the 21-mer oligo has no homology sequence with lacZYA, and no mRNA is transcribed from the operator, suggests that the 21-mer oligo inhibits target gene expression by an antigene mechanism. To simulate the kinetics of lac operon gene expression in the presence of antigene oligos, a genetically structured kinetic model, which includes transport of oligo into the cell, growth of bacteria cells, and lac operon gene expression, was developed. Predictions of the kinetic model fit the experimental data quite well after adjustment of the value of the oligonucleotide transport rate constant (9.0 x 10(-)(3) min(-)(1)) and oligo binding affinity constant (1.05 x 10(6) M(-)(1)). Our values for these two adjusted parameters are in the range of reported literature values.
Cheng
B
B
Department of Bioengineering, University of Toledo, Toledo, Ohio 43606, USA.
Fournier
R L
RL
Relue
P A
PA
Schisler
J
J
D001692:Biological Transport; D002455:Cell Division / Q000187:drug effects / Q000235:genetics; D003198:Computer Simulation; D000242:Cyclic AMP / Q000378:metabolism; D004926:Escherichia coli / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism; D015964:Gene Expression Regulation, Bacterial / Q000187:drug effects; D007544:Isopropyl Thiogalactoside / Q000493:pharmacokinetics; D007700:Kinetics; D008962:Models, Theoretical; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D009876:Operon; D001616:beta-Galactosidase / Q000235:genetics
D016376:Oligonucleotides, Antisense; D007544:Isopropyl Thiogalactoside; D000242:Cyclic AMP; D001616:beta-Galactosidase